Study guide
3.3 Venue Selection, Open Access, and Congress Strategy
Certified Medical Publication Professional CMPP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Preparation Strategy
1.1 ISMPP CMPP Certification Overview, Eligibility & Exam Format 1.2 Recertification, Continuing Education (CE) Credits & ISMPP U 1.3 Core Reference Hierarchy, Primary Documents & Test-Taking Strategy
2 Chapter 2: Publication Planning: Strategy, Environment & Scientific Platform
2.1 Medical Publication Lifecycle & Strategic Planning Frameworks 2.2 Therapeutic Landscape Analysis, Unmet Needs & Gap Analysis 2.3 Scientific Communication Platforms and Evidence-Based Language
3 Chapter 3: Publication Planning: Governance, Steering Committees & Venue Selection
3.1 Publication Steering Committees: Charters, Roles & Scientific Governance 3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators 3.3 Venue Selection, Open Access, and Congress Strategy
4 Chapter 4: Publication Planning: Operations, Contracting, Global Alignment & Compliance
4.1 Publication Agreements, Review Rights, Compensation & Disclosure 4.2 Milestones, Gantt Charts, Budgeting & Vendor/Agency Management 4.3 Global vs. Regional/Local Publication Alignment & Localization 4.4 Publication SOPs, Documentation, Quality Control & Audit Readiness
5 Chapter 5: Reporting Guidelines: Foundational Standards & Trial Reporting
5.1 EQUATOR and Design-Specific Reporting Guidelines 5.2 CONSORT 2025 & Flow Diagrams for Randomized Trials 5.3 SPIRIT 2025: Standard Protocol Items for Interventional Trials
6 Chapter 6: Reporting Guidelines: Observational, Reviews & Preclinical
6.1 PRISMA 2020 for Systematic Reviews & Meta-Analyses 6.2 STROBE & RECORD for Observational and Routinely Collected Data 6.3 ARRIVE 2.0 for In Vivo Animal Research
7 Chapter 7: Specialized Reporting, Plain Language Summaries & Congress Submissions
7.1 STARD 2015, CARE, and Specialized Reporting Guidelines 7.2 Plain-Language Summaries and Patient Partnership 7.3 GPCAP 2026: Congress Abstracts, Presentations & Encores 7.4 Digital Publication Features, Accessibility, and Social Dissemination
8 Chapter 8: Manuscript Lifecycle: Drafting, Peer Review, Open Access & Metrics
8.1 Manuscript Development, Author Review, and Sponsor Boundaries 8.2 Peer Review, Rebuttals, Revisions, and Appeals 8.3 Preprints, Creative Commons & Current Open-Access Requirements 8.4 Post-Publication Metrics and Correcting the Record
9 Chapter 9: Ethical Principles: GPP 2022, Authorship Criteria & Contributorship
9.1 Good Publication Practice 2022: Principles, Scope & Application 9.2 ICMJE Authorship Criteria and Qualification Scenarios 9.3 Nonauthor Contributors, Acknowledgments, and CRediT
10 Chapter 10: Ethics & Transparency: Ghostwriting, Writing Assistance, COI & Disclosure
10.1 Ghostwriting, Guest Authorship, and Authorship Disputes 10.2 Professional Medical Writing: Roles, Authorship, Disclosure & Funding 10.3 Disclosure of Interests and Publication Transparency 10.4 Open Payments, EFPIA Codes & Publication-Related Transfers of Value
11 Chapter 11: Compliance & Legal: Clinical Trial Registration, Data Sharing, Regulatory & Ethics
11.1 Trial Registration and Results Disclosure: US, EU, and ICMJE 11.2 Clinical-Trial Data-Sharing Statements and FAIR Principles 11.3 FDA SIUU Guidance & Promotional/Scientific Communication Boundaries 11.4 2024 Declaration of Helsinki, Ethics Review, Privacy & Copyright
3.3 Venue Selection, Open Access, and Congress Strategy
Key Takeaways Explain This Topic AI
Select journals and congresses for audience, scope, editorial quality, indexing and discoverability, article type, timelines, policies, cost, and funder compliance—not a single journal metric.
Journal Impact Factor is a journal-level citation measure and should not be used as a proxy for the quality of an individual article or author.
Open access availability, copyright ownership, repository deposit, and license are separate questions; read the current funder, institutional, and venue terms for the specific work.
Deceptive publishing assessment uses multiple verifiable signals and the Think. Check. Submit. process; absence from one directory alone is not proof of misconduct.
Late-breaking, encore, prior-publication, embargo, copyright, and presentation requirements are venue-specific and must be checked before submission.
Last updated: October 2026
Venue Selection, Open Access, and Congress Strategy
A venue is appropriate when it brings valid evidence to the people who can use it while meeting scientific, ethical, contractual, and access requirements. Prestige can matter for reach, but a single metric is not a strategy.
Journal selection matrix
Build a short list from the manuscript's actual design, topic, audience, and article type. Verify each candidate on the publisher's current site and in authoritative databases. Useful criteria include:
Criterion Questions to verify
Scope and audience Does the journal publish this design and topic? Who reads it?
Editorial quality Is peer review described? Are editors and ownership identifiable? Are corrections and ethics policies available?
Discoverability Is the journal represented in the relevant bibliographic services? What exactly is indexed?
Format Does it accept the article type, length, supplement, data, PLS, or digital asset?
Timing Are published decision times credible? Is rapid handling essential or merely preferred?
Access and rights What access route, license, copyright, repository, and reuse terms apply?
Cost What APC, page, color, editing, data, or optional service charges apply?
Compliance Do funder, institution, trial, data-sharing, and reporting requirements fit?
Use a weighted matrix only if its assumptions are visible. A numeric score can conceal a fatal mismatch such as prohibited article type, missed funder rule, or unsuitable readership.
Responsible use of metrics
The Journal Impact Factor (JIF) is calculated for a journal using citations to selected recent content over a defined window. It is skewed by citation distributions, document mix, field, and editorial practices. CiteScore and other journal indicators use different databases and windows. None measures the methodological quality of a particular submitted paper.
DORA principles support assessing research on its own merits rather than substituting journal metrics. A focused specialty journal may reach the clinicians who need the evidence better than a general journal with a higher metric. Consider readership, article-level discoverability, guideline relevance, and accessibility alongside responsible metrics.
Be precise about indexing. MEDLINE is a curated National Library of Medicine database. PubMed is a search platform that includes MEDLINE and additional records. A journal's statement that an article “appears in PubMed” is not necessarily the same as MEDLINE journal indexing. Verify claims using the authoritative service rather than a logo on the journal site.
Open access, rights, and licenses
“Open access” describes reader availability; it does not by itself identify the owner, permitted reuse, or repository route.
Gold open access: the final article is openly available from the publisher, sometimes with an APC.
Hybrid: an individual article is made open in an otherwise subscription journal.
Green or repository access: an allowed version is deposited in a repository under the applicable timing and license.
Diamond: readers and authors are not charged, usually because another organization supports the venue.
These labels do not guarantee one copyright or license arrangement. Read the publishing agreement.
Common Creative Commons licenses differ. CC BY permits reuse and adaptation, including commercial reuse, with attribution and other conditions. CC BY-NC restricts licensed reuse to noncommercial purposes. CC BY-ND does not authorize distribution of adaptations under the license. Third-party material may be excluded even when the article carries a license.
Funder policies change. Current cOAlition S requirements emphasize immediate open access through permitted routes and generally favor CC BY while recognizing stated alternatives or exceptions. The current NIH Public Access Policy applies to covered manuscripts accepted on or after July 1, 2025 and requires submission of the accepted manuscript upon acceptance for public availability without embargo on the official publication date. Apply the policy, award, acceptance date, and venue agreement that actually govern the paper; do not collapse all funders into one “Plan S” rule.
Budget from a current quotation or official fee page. APCs differ by journal, article type, membership, institution, country, agreement, tax, and optional service. There is no reliable universal APC range.
Deceptive or low-quality publishers
Use Think. Check. Submit. to verify identity, ownership, contact details, editorial board, peer-review process, fees, preservation, policies, indexing claims, and recognized memberships. Warning signs include guaranteed acceptance, implausibly fast review, fabricated metrics, copied sites, unverifiable editors, hidden fees, misleading addresses, and aggressive irrelevant solicitation.
No single signal proves deception. A legitimate new or regional journal may not be in MEDLINE or DOAJ, and a directory listing is not a complete quality guarantee. If material claims cannot be verified, pause rather than submit confidential work or pay a fee. Record the evidence and choose a venue with transparent, credible operations.
Congress selection and deadlines
Match the congress to the scientific audience, geography, topic, format, timing, publication status, access, and cost. Read the current call for abstracts. It controls eligibility, word or character limit, author cap, data requirements, embargo, prior presentation, trial registration, disclosure, copyright, presentation format, accessibility, and withdrawal.
A late-breaking abstract (LBA) is not universally defined by a fixed number of weeks or a requirement for a placeholder. Each congress sets eligibility and process. Many reserve the category for important data unavailable by the regular deadline for reasons inherent to the study schedule, but exact criteria vary. Do not hold completed data merely to seek LBA status.
Encores and prior dissemination
An encore repeats or adapts previously presented work for another audience. It may be permitted when the receiving meeting allows it, prior presentation is disclosed, copyright and license terms are respected, the submission is not misrepresented as new, and any translation or adaptation is accurate. Some congresses prohibit encores or limit them by geography, meeting type, or elapsed time.
Check whether an abstract publication, preprint, press release, or prior poster affects journal or congress eligibility. ICMJE permits certain preliminary dissemination but the target venue's policy and embargo still matter. Coordinate simultaneous congress and journal release only with written policies and editor or congress approval.
Important
In selection scenarios, verify the controlling venue and funder rules. Reject universal assumptions about JIF, APCs, LBA timing, encore permission, or open-access licenses.